# 225 Portal And Support Go/No-Go Decision

Gate reference: `PSG_225_PORTAL_SUPPORT_BASELINE_COMPLETION_V1`

Verdict: `approved`

Baseline scope: `repository_runnable_patient_account_records_communications_support_entry_and_support_workspace_baseline`

Approval boundary: Approves the repository-runnable patient account, records, communications, support entry, support workspace, masking, replay-safe fallback, and patient-support parity baseline. It does not approve credentialled live NHS login, live provider replay, production clinical-safety signoff, DSPT signoff, or operational deployment readiness.

## Formal Decision

The portal and support baseline is `approved` for Phase 3 entry.

This means:

- the repository now has one coherent patient/support product family across patient account, records, communications, support entry, support ticket, masking, replay, and read-only fallback routes
- the definitive continuity suite passed and the repository-owned defects discovered during that suite were fixed before exit
- later Phase 3 work must consume this baseline rather than reopen it
- live-provider and production-signoff proof are still out of scope and explicitly not approved here

## Score Summary

- approved rows: `9`
- go-with-constraints rows: `0`
- withheld rows: `0`
- open carry-forward items: `5`

## Decision Questions

### Q225_001

**Question**: Are tasks 210 to 224 complete, source-traceable, and internally coherent?

**Answer**: `approved`

Yes. The checklist marks 210 through 224 complete, the conformance rows bind each capability family to owning tasks and source references, and the merge/seam log reports no unresolved cross-cutting gap.

Evidence: prompt/checklist.md<br>data/analysis/225_conformance_rows.json<br>data/analysis/225_evidence_manifest.csv<br>data/analysis/223_merge_gap_log.json

### Q225_002

**Question**: Did the definitive continuity suite from 224 pass with machine-readable evidence?

**Answer**: `approved`

Yes. Seq 224 reports overall passed status, no blocked external cases, explicit family-level pass status, and resolved repository-owned defects captured in the defect log.

Evidence: data/test/224_suite_results.json<br>data/test/224_defect_log_and_remediation.json<br>tools/test/validate_crosscutting_continuity_suite.py

### Q225_003

**Question**: Do patient account, records, communications, support entry, support workspace, masking, and fallback routes now behave like one coherent product family?

**Answer**: `approved`

Yes. The approved rows cover all required route families and bind them to one same-shell, continuity-preserving, evidence-first product grammar rather than separate local route semantics.

Evidence: data/analysis/225_conformance_rows.json<br>docs/governance/225_portal_and_support_conformance_scorecard.md<br>data/test/224_suite_results.json

### Q225_004

**Question**: Are patient and support surfaces demonstrably aligned to the same Phase 2 identity, status, and capability truth?

**Answer**: `approved`

Yes. Seq 223 publishes one shared identity and status bundle, resolves the earlier merge seams, and the browser-visible parity suite confirms the same cause classes and continuity labels across patient and support routes.

Evidence: data/contracts/223_crosscutting_identity_status_surface_bundle.json<br>data/analysis/223_patient_support_status_parity_matrix.csv<br>tests/playwright/223_patient_support_identity_status_integration.spec.js

### Q225_005

**Question**: Are record artifacts and communication artifacts parity-safe and restriction-safe?

**Answer**: `approved`

Yes. Record parity, release gating, visualization fallback, communication visibility, and receipt alignment are all bound to the same current artifact and status truth, and the continuity suite verifies the restricted and read-only variants in browser-visible form.

Evidence: data/analysis/213_record_parity_and_release_matrix.csv<br>data/analysis/214_preview_visibility_and_placeholder_matrix.csv<br>data/analysis/217_record_chart_table_fallback_matrix.csv<br>data/test/224_record_parity_and_visibility_cases.csv

### Q225_006

**Question**: Which evidence is repository-runnable today, and which later live-environment proofs still remain outside this baseline?

**Answer**: `approved`

All nine conformance rows are backed by repository-runnable artifacts. Two carry-forward items remain explicitly outside this baseline: credentialled live-provider replay proof and production clinical, security, and operational signoff.

Evidence: data/analysis/225_conformance_rows.json<br>data/analysis/225_open_items_and_phase3_carry_forward.json<br>docs/governance/208_phase2_mock_now_vs_crosscutting_boundary.md

### Q225_007

**Question**: Which items are intentionally deferred to Phase 3 tasks 226+, and why are they not blockers for the current exit?

**Answer**: `approved`

The triage workspace contract pack, queue and duplicate fairness pack, and endpoint decision and escalation pack are explicitly deferred to 226 through 229. They are not blockers because the current gate approves only the patient/support baseline, not the later human-checkpoint write surfaces built on top of it.

Evidence: data/analysis/225_open_items_and_phase3_carry_forward.json<br>prompt/226.md<br>prompt/227.md<br>prompt/228.md<br>prompt/229.md


## Approval Statement

This is an honest baseline approval, not a production release approval. Any future change that would alter patient/support identity truth, continuity tuples, masking laws, replay recovery, or artifact parity must be recorded as a later change, not smuggled into Phase 3 implementation as local UI logic.
